Osteoclasts: More than 'bone eaters'

Trends in Molecular Medicine

Volumn 20, Issue 8, 2014, Pages 449-459

  Charles, Julia F ^a   Aliprantis, Antonios O ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bone remodeling; Osteoblast; Osteoclast; Osteopetrosis; Osteoporosis; PTH

Indexed keywords

ALBERS SCHOENBERG DISEASE; ANIMAL; BONE; BONE DEVELOPMENT; BONE REMODELING; CYTOLOGY; FIBROUS DYSPLASIA; HUMAN; METABOLISM; OSTEOCLAST; OSTEOCLASTOMA; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGY;

ANIMALS; BONE AND BONES; BONE REMODELING; BONE RESORPTION; FIBROUS DYSPLASIA OF BONE; GIANT CELL TUMOR OF BONE; HUMANS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPETROSIS; OSTEOPOROSIS;

EID: 84905560371     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.06.001     Document Type: Review

References (132)

1. Sims N.A., Martin T.J. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 2014, 3:481.
2. Teti A. Mechanisms of osteoclast-dependent bone formation. Bonekey Rep. 2013, 2:449.
3. Boyle W.J., et al. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
4. Lacey D.L., et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 2012, 11:401-419.
5. Boyce B.F. Advances in the regulation of osteoclasts and osteoclast functions. J. Dent. Res. 2013, 92:860-867.
6. US Department of Health and Human Services Bone Health and Osteoporosis: A Report of the Surgeon General 2004, US Department of Health and Human Services.
7. Abrahamsen B., et al. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos. Int. 2009, 20:1633-1650.
8. Jones D., et al. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J. Clin. Invest. 2011, 121:2534-2542.
9. Segovia-Silvestre T., et al. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum. Genet. 2009, 124:561-577.
10. Sobacchi C., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 2007, 39:960-962.
11. Sobacchi C., et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat. Rev. Endocrinol. 2013, 9:522-536.
12. Kolliker A. Die normale Resorption des Knochengewebes und ihre Bedeutung die Entstehung der typischen Knochenformen 1873, FCW Vogel.
13. Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 2013, 19:179-192.
14. Bedi B., et al. Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E725-E733.
15. Guihard P., et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 2012, 30:762-772.
16. Tawfeek H., et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS ONE 2010, 5:e12290.
17. Henriksen K., et al. Osteoclast activity and subtypes as a function of physiology and pathology - implications for future treatments of osteoporosis. Endocr. Rev. 2011, 32:31-63.
18. Everts V., et al. Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions. Biochim. Biophys. Acta 2009, 1792:757-765.
19. Tang Y., et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 2009, 15:757-765.
20. Xian L., et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med. 2012, 18:1095-1101.
21. Zhen G., et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med. 2013, 19:704-712.
22. Karsdal M.A., et al. Are nonresorbing osteoclasts sources of bone anabolic activity?. J. Bone Mineral Res. 2007, 22:487-494.
23. Gerritsen E.J., et al. Autosomal recessive osteopetrosis: variability of findings at diagnosis and during the natural course. Pediatrics 1994, 93:247-253.
24. Pangrazio A., et al. RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations. J. Bone Mineral Res. 2012, 27:342-351.
25. Del Fattore A., et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J. Med. Genet. 2006, 43:315-325.
26. Marzia M., et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 2000, 151:311-320.
27. -/- mice. Bone 2009, 44:199-207.
28. Li C.Y., et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J. Bone Miner. Res. 2006, 21:865-875.
29. Lotinun S., et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J. Clin. Invest. 2013, 123:666-681.
30. Dai X.M., et al. Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J. Bone Miner. Res. 2004, 19:1441-1451.
31. Sakagami N., et al. Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice. Micron 2005, 36:688-695.
32. Wang Z.Q., et al. Bone and haematopoietic defects in mice lacking c-fos. Nature 1992, 360:741-745.
33. Kimura H., et al. Cthrc1 is a positive regulator of osteoblastic bone formation. PLoS ONE 2008, 3:e3174.
34. Takeshita S., et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J. Clin. Invest. 2013, 123:3914-3924.
35. Matsuoka K., et al. Osteoclast-derived complement component 3a stimulates osteoblast differentiation. J. Bone Miner. Res. 2014, 10.1002/jbmr.2187.
36. Ryu J., et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J. 2006, 25:5840-5851.
37. Pederson L., et al. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20764-20769.
38. Ishii M., et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009, 458:524-528.
39. Ishii M., et al. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J. Exp. Med. 2010, 207:2793-2798.
40. Matsuo K., Otaki N. Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh. Migr. 2012, 6:148-156.
41. Irie N., et al. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J. Biol. Chem. 2009, 284:14637-14644.
42. Zhao C., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006, 4:111-121.
43. Furuya Y., et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kappaB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J. Biol. Chem. 2013, 288:5562-5571.
44. Bukhari M. The National Osteoporosis Guideline Group's new guidelines: what is new?. Rheumatology 2009, 48:327-329.
45. Rogers M.J., et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49:34-41.
46. Pierroz D.D., et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J. Biol. Chem. 2010, 285:28164-28173.
47. Black D.M., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 2003, 349:1207-1215.
48. Finkelstein J.S., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 2003, 349:1216-1226.
49. Cosman F., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 2011, 26:503-511.
50. Tsai J.N., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013, 382:50-56.
51. Xu X.L., et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?. J. Transl. Med. 2013, 11:303.
52. Pennypacker B.L., et al. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J. Bone Miner. Res. 2014, 10.1002/jbmr.2211.
53. Rhee Y., et al. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J. Biol. Chem. 2013, 288:29809-29820.
54. Langdahl B., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J. Bone Miner. Res. 2012, 27:2251-2258.
55. Cusick T., et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J. Bone Miner. Res. 2012, 27:524-537.
56. Yamane H., et al. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 2009, 44:1055-1062.
57. McClung M.R., et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2014, 370:412-420.
58. van Lierop A.H., et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J. Bone Miner. Res. 2011, 26:2804-2811.
59. Takahashi N., et al. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Front. Biosci. 2011, 16:21-30.
60. Balke M., et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010, 10:462.
61. Tse L.F., et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008, 42:68-73.
62. Thomas D., et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010, 11:275-280.
63. Branstetter D.G., et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin. Cancer Res. 2012, 18:4415-4424.
64. Monge J., et al. Fibrous dysplasia in a 120,000+ year old Neandertal from Krapina, Croatia. PLoS ONE 2013, 8:e64539.
65. Riddle N.D., Bui M.M. Fibrous dysplasia. Arch. Pathol. Lab. Med. 2013, 137:134-138.
66. Vilardaga J.P., et al. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell. Mol. Life Sci. 2011, 68:1-13.
67. Regard J.B., et al. Wnt/beta-catenin signaling is differentially regulated by Galpha proteins and contributes to fibrous dysplasia. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:20101-20106.
68. Riminucci M., et al. Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone 2003, 33:434-442.
69. Yamamoto T., et al. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J. Clin. Invest. 1996, 98:30-35.
70. Thomsen M.D., Rejnmark L. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Calcif. Tissue Int. 2014, 94:384-395.
71. Boyce A.M., et al. Denosumab treatment for fibrous dysplasia. J. Bone Miner. Res. 2012, 27:1462-1470.
72. Ganda K., Seibel M.J. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. Osteoporos. Int. 2014, 25:777-782.
73. Taranta A., et al. Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am. J. Pathol. 2003, 162:57-68.
74. Silverberg S.J., et al. Skeletal disease in primary hyperparathyroidism. J. Bone Miner. Res. 1989, 4:283-291.
75. Ohishi M., et al. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Am. J. Pathol. 2009, 174:2160-2171.
76. Morrison S.J., Scadden D.T. The bone marrow niche for haematopoietic stem cells. Nature 2014, 505:327-334.
77. Mansour A., et al. Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J. Exp. Med. 2012, 209:537-549.
78. Jacome-Galarza C., et al. Altered hematopoietic stem cell and osteoclast precursor frequency in cathepsin K null mice. J. Cell. Biochem. 2014, 115:1449-1457.
79. Lymperi S., et al. Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood 2011, 117:1540-1549.
80. Flores C., et al. Osteoclasts are not crucial for hematopoietic stem cell maintenance in adult mice. Haematologica 2013, 98:1848-1855.
81. Miyamoto K., et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J. Exp. Med. 2011, 208:2175-2181.
82. Lapid K., et al. Egress and mobilization of hematopoietic stem and progenitor cells: a dynamic multi-facet process. StemBook 2008, Harvard Stem Cell Institute. http://www.stembook.org/.
83. Morrison S.J., et al. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1908-1913.
84. Pusic I., DiPersio J.F. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr. Opin. Hematol. 2010, 17:319-326.
85. Dale D.C., et al. The Severe Chronic Neutropenia International Registry: 10-year follow-up report. Support. Cancer Ther. 2006, 3:220-231.
86. Borzutzky A., et al. Osteoporosis in children with severe congenital neutropenia: bone mineral density and treatment with bisphosphonates. J. Pediatr. Hematol. Oncol. 2006, 28:205-209.
87. Li S., et al. A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization. J. Cell. Physiol. 2013, 228:1002-1009.
88. Takahashi T., et al. Overexpression of the granulocyte colony-stimulating factor gene leads to osteoporosis in mice. Lab. Invest. 1996, 74:827-834.
89. Takamatsu Y., et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 1998, 92:3465-3473.
90. Kollet O., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 2006, 12:657-664.
91. Kook S., et al. The nucleotide sugar UDP-glucose mobilizes long-term repopulating primitive hematopoietic cells. J. Clin. Invest. 2013, 123:3420-3435.
92. Sun S., et al. The development and characterization of an ELISA specifically detecting the active form of cathepsin K. Clin. Biochem. 2013, 46:1601-1606.
93. Munoz-Torres M., et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas 2009, 64:188-192.
94. Wiktor-Jedrzejczak W.W., et al. Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation. J. Exp. Med. 1982, 156:1516-1527.
95. Akiyama T., et al. RANKL-RANK interaction in immune regulatory systems. World J. Orthop. 2012, 3:142-150.
96. Kanaya T., et al. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat. Immunol. 2012, 13:729-736.
97. Kiechl S., et al. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 2013, 19:358-363.
98. Sigl V., Penninger J.M. RANKL/RANK - from bone physiology to breast cancer. Cytokine Growth Factor Rev. 2014, 25:205-214.
99. Jacquin C., et al. Identification of multiple osteoclast precursor populations in murine bone marrow. J. Bone Miner. Res. 2006, 21:67-77.
100. Charles J.F., et al. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Invest. 2012, 122:4592-4605.
101. Aliprantis A.O., et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J. Clin. Invest. 2008, 118:3775-3789.
102. Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol. Res. 2013, 57:172-184.
103. Grassi F., et al. T cell suppression by osteoclasts in vitro. J. Cell. Physiol. 2011, 226:982-990.
104. Danilin S., et al. Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology 2012, 1:1484-1494.
105. Sawant A., et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 2013, 73:672-682.
106. + myeloid-derived suppressor cells. PLoS ONE 2012, 7:e48871.
107. + T cells. Blood 2010, 116:210-217.
108. + T cells. J. Immunol. 2009, 182:5477-5487.
109. + T-cells suppress bone resorption in vitro. PLoS ONE 2012, 7:e38199.
110. + CD8 T-cells limit bone loss in mice. Bone 2013, 56:163-173.
111. Bozec A., et al. T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci. Transl. Med. 2014, 6:235ra260.
112. Axmann R., et al. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 2008, 67:1603-1609.
113. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin. Oncol. 2010, 37(Suppl. 2):S2-S14.
114. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004, 350:1655-1664.
115. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593.
116. Korpal M., et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 2009, 15:960-966.
117. Brown J.E., Coleman R.E. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat. Rev. Clin. Oncol. 2012, 9:110-118.
118. Young R.J., Coleman R.E. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol. 2013, 9:633-643.
119. Negishi-Koga T., et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med. 2011, 17:1473-1480.
120. Del Fattore A., et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J. Bone Miner. Res. 2008, 23:380-391.
121. Angel N.Z., et al. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J. Bone Miner. Res. 2000, 15:103-110.
122. Hayman A.R., Cox T.M. Tartrate-resistant acid phosphatase knockout mice. J. Bone Miner. Res. 2003, 18:1905-1907.
123. Walker E.C., et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J. Bone Miner. Res. 2008, 23:2025-2032.
124. Ota K., et al. Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors. Bone 2013, 57:68-75.
125. Kim B.J., et al. Afamin secreted from nonresorbing osteoclasts acts as a chemokine for preosteoblasts via the Akt-signaling pathway. Bone 2012, 51:431-440.
126. Vukicevic S., Grgurevic L. BMP-6 and mesenchymal stem cell differentiation. Cytokine Growth Factor Rev. 2009, 20:441-448.
127. Ota K., et al. Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J. Cell. Biochem. 2013, 114:1901-1907.
128. Grano M., et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:7644-7648.
129. Chen H.T., et al. Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt, c-Src, and AP-1 signaling pathway. PLoS ONE 2012, 7:e38378.
130. Kreja L., et al. Non-resorbing osteoclasts induce migration and osteogenic differentiation of mesenchymal stem cells. J. Cell. Biochem. 2010, 109:347-355.
131. Sanchez-Fernandez M.A., et al. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PLOS ONE 2008, 3:e3537.
132. Kubota K., et al. PDGF BB purified from osteoclasts acts as osteoblastogenesis inhibitory factor (OBIF). J. Biomol. Tech. 2002, 13:62-71.